Viking Therapeutics: A High-Risk, High-Reward Biotech Opportunity
Join us as we dive into Viking Therapeutics (VKTX), a clinical-stage biotech company with a promising pipeline. Our experts rate its business strength, management, financials, and valuation, revealing the potential for substantial returns amidst significant risks. Is this stock worth the gamble? Watch to find out!
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 838% as of 7/15/2025 and measured against the S&P 500 returns of 180% as of 7/15/2025. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
